risperidone has been researched along with Arrhythmia in 13 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 9.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "Sertindole did not increase all-cause mortality, but cardiac mortality was higher and suicide attempts may be lower with sertindole." | 6.75 | Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). ( Crocq, MA; Drici, MD; Everitt, B; Hall, GC; Lader, MH; Le Jeunne, C; Mann, RD; Mittoux, A; Moore, ND; Naber, D; Peuskens, J; Priori, S; Sturkenboom, M; Tanghøj, P; Thibaut, F; Thomas, SH; Toumi, M, 2010) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 5.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "Patients with schizophrenia treated with clozapine, haloperidol, risperidone, or thioridazine; a control group of patients with glaucoma; and a control group of patients with psoriasis." | 3.71 | Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. ( Bilker, WB; Glasser, DB; Hennessy, S; Kimmel, SE; Knauss, JS; Margolis, DJ; Morrison, MF; Reynolds, RF; Strom, BL, 2002) |
| "Sertindole did not increase all-cause mortality, but cardiac mortality was higher and suicide attempts may be lower with sertindole." | 2.75 | Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). ( Crocq, MA; Drici, MD; Everitt, B; Hall, GC; Lader, MH; Le Jeunne, C; Mann, RD; Mittoux, A; Moore, ND; Naber, D; Peuskens, J; Priori, S; Sturkenboom, M; Tanghøj, P; Thibaut, F; Thomas, SH; Toumi, M, 2010) |
| "Aripiprazole has the most consistent evidence of symptom improvement; however, this improvement is small." | 2.53 | Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use. ( Cocker, KE; Reese, TR; Thiel, DJ, 2016) |
| " This is because of their efficacy in the treatment of several psychiatric disorders, ease of administration, and absence of the well-known extrapyramidal adverse effects long-attributed to the standard dopamine blocking anti-psychotic medications." | 2.42 | Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician. ( Bailey, RK, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, L | 1 |
| Sun, H | 1 |
| Kram, BL | 1 |
| Kram, SJ | 1 |
| Brooks, KR | 1 |
| Reese, TR | 1 |
| Thiel, DJ | 1 |
| Cocker, KE | 1 |
| Thomas, SH | 1 |
| Drici, MD | 1 |
| Hall, GC | 1 |
| Crocq, MA | 1 |
| Everitt, B | 1 |
| Lader, MH | 1 |
| Le Jeunne, C | 1 |
| Naber, D | 1 |
| Priori, S | 1 |
| Sturkenboom, M | 1 |
| Thibaut, F | 1 |
| Peuskens, J | 1 |
| Mittoux, A | 1 |
| Tanghøj, P | 1 |
| Toumi, M | 1 |
| Moore, ND | 1 |
| Mann, RD | 1 |
| Pollak, PT | 1 |
| Verjee, ZH | 1 |
| Lyon, AW | 1 |
| Suzuki, Y | 1 |
| Ono, S | 1 |
| Fukui, N | 1 |
| Sugai, T | 1 |
| Watanabe, J | 1 |
| Tsuneyama, N | 1 |
| Someya, T | 1 |
| Hennessy, S | 1 |
| Bilker, WB | 1 |
| Knauss, JS | 1 |
| Margolis, DJ | 1 |
| Kimmel, SE | 1 |
| Reynolds, RF | 1 |
| Glasser, DB | 1 |
| Morrison, MF | 1 |
| Strom, BL | 1 |
| Bailey, RK | 1 |
| Ando, K | 1 |
| Sugiyama, A | 1 |
| Takahara, A | 1 |
| Satoh, Y | 1 |
| Ishizaka, T | 1 |
| Nakamura, Y | 1 |
| Hashimoto, K | 1 |
| Wang, PS | 1 |
| Schneeweiss, S | 1 |
| Setoguchi, S | 1 |
| Patrick, A | 1 |
| Avorn, J | 1 |
| Mogun, H | 1 |
| Choudhry, NK | 1 |
| Brookhart, MA | 1 |
| Perlis, RH | 1 |
| Czekalla, J | 1 |
| Beasley, CM | 1 |
| Dellva, MA | 1 |
| Berg, PH | 1 |
| Grundy, S | 1 |
| Wilton, LV | 1 |
| Heeley, EL | 1 |
| Pickering, RM | 1 |
| Shakir, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study[NCT00856583] | Phase 3 | 9,809 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 31 |
| Risperidone | 12 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon the Medical Dictionary for Regulatory Activities (MedDRA) terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 17 |
| Risperidone | 8 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 14 |
| Risperidone | 21 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 13 |
| Risperidone | 21 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 19 |
| Risperidone | 28 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 34 |
| Risperidone | 32 |
The analysis was based on time from start of study drug until stop of study drug for any reason other than sponsor closure of the study (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 3136 |
| Risperidone | 2597 |
The analysis was based on time from start of study drug to first hospitalisation during the WRT+30 days period (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 174 |
| Risperidone | 149 |
"The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 68 |
| Risperidone | 76 |
The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 43 |
| Risperidone | 65 |
Second primary endpoint: a serious adverse event where the patient was hospitalised and for which the Independent Safety Committee (ISC) classified the event as a cardiac event with documented arrhythmia. The analysis of this outcome was not performed due to low number of events. The presented analysis is a replacement analysis using all cardiac events, including arrhythmias, that required hospitalisation (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 10 |
| Risperidone | 6 |
The analysis was based on all deaths from the Whole Randomised Treatment (WRT)+30 days period and the Only Randomised Treatment (ORT) period, respectively (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) | |
|---|---|---|
| Number of deaths (WRT+30 days) | Number of deaths (ORT) | |
| Risperidone | 61 | 44 |
| Sertindole | 64 | 40 |
3 reviews available for risperidone and Arrhythmia
| Article | Year |
|---|---|
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Behavior Therapy; | 2016 |
Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.
Topics: Adult; Aged; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Black or African American; | 2003 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabete | 2007 |
2 trials available for risperidone and Arrhythmia
| Article | Year |
|---|---|
Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Arrhythmias, Cardiac; Female; Hear | 2010 |
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agent | 2001 |
8 other studies available for risperidone and Arrhythmia
| Article | Year |
|---|---|
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant | 2008 |
Implications of atypical antipsychotic prescribing in the intensive care unit.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Benzo | 2015 |
Risperidone-induced QT prolongation following overdose correlates with serum drug concentration and resolves rapidly with no evidence of altered pharmacokinetics.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Arrhythmias, Cardiac; Drug Overdose; Fe | 2011 |
Dose-dependent increase in the QTc interval in aripiprazole treatment after risperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; E | 2011 |
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data.
Topics: Adult; Aged; Antipsychotic Agents; Arrhythmias, Cardiac; Clozapine; Cohort Studies; Confidence Inter | 2002 |
Analysis of proarrhythmic potential of antipsychotics risperidone and olanzapine in anesthetized dogs.
Topics: Action Potentials; Anesthesia; Animals; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; | 2007 |
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepine | 2007 |
Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Cohort | 2001 |